A placebo-controlled phase 2 trial testing a 15-day course of nirmatrelvir–ritonavir (Paxlovid) against placebo in adults with Long COVID, finding no significant improvement in outcomes at day 28 compared with placebo.
Treatment & Management
Nirmatrelvir–Ritonavir Versus Placebo–Ritonavir in Individuals With Long COVID in the USA (PAX LC)
April 3, 2025
A placebo-controlled phase 2 trial of a 15-day Paxlovid course in adults with Long COVID found no significant improvement at day 28.
Save For Later
Email yourself a link to this article.
Saved. Check your email app.
Something didn't go through — try again.